New sepsis data indicates very good efficacy in Apta-1 treated primates

2018-11-14

Aptahem (publ) announce today that the extended exploratory sepsis study in primates has shown positive results. This increases the hope of being able to show good efficacy also in upcoming and more extensive confirmatory studies. After the company announced...

Read More

Aptahem reports good safety profile for Apta-1 after concluded toxicology- and safety program (non-GLP)

2018-10-10

Aptahem (publ) announce today that the final reports from the non-regulated GLP (Good Laboratory Practice) toxicology- and safety studies in Apta-1’s pre-clinical program show positive results. The results indicate that higher dosages of Apta-1, than previously estimated, shows a...

Read More

Yorkville Advisors Global subscribe for 158,730 shares in Aptahem by converting convertibles

2018-09-14

On 26 June 2018, Aptahem (publ) signed an issuance agreement with YA II PN Ltd, a fund represented by the United States-based Yorkville Advisors Global (“Yorkville”), which describes the terms of issuance of and subscription to notes convertible into...

Read More

Apta-1 has in the ongoing toxicology program indicated a good safety profile that resulted in a greater substance need, which delays the program

2018-08-29

Aptahem AB (publ) announce today that the company’s ongoing pre-clinical toxicology development program is delayed pending the manufacturing of more Apta-1. The drug candidate Apta-1 has in the company’s ongoing toxicology program indicated a good safety profile, which has...

Read More

Yorkville Advisors Global subscribe for 99 502 shares in Aptahem by converting convertibles

2018-07-20

On 26 June 2018, Aptahem (publ) signed an issuance agreement with YA II PN Ltd, a fund represented by the United States-based Yorkville Advisors Global (“Yorkville”), which describes the terms of issuance of and subscription to notes convertible into...

Read More

Aptahem enters into an agreement with Yorkville Advisors Global securing financing of up to MSEK 20

2018-06-27

Aptahem AB (publ), a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved in the disease process, today announce its entry into an issuance agreement with...

Read More

Aptahem and Seattle Children’s Research Institute partner to study experimental sepsis drug

2018-06-13

Aptahem AB (publ) announces a partnership with Seattle Children’s Research Institute to explore the mechanisms underlying their new aptamer-based therapeutic for acute and chronic inflammatory conditions including sepsis. Sepsis is a complex and potentially life-threatening condition that occurs when...

Read More

Aptahem to start toxicology programme for Apta-1

2018-05-15

Aptahem AB (publ.), a biotech company that develops aptamer-based drugs for the treatment of life-threatening conditions in which coagulation and inflammation interact in the disease process, can today announce that it will start its first toxicology trials this week....

Read More

Save lives: Clean your hands!

2018-05-04

The 5 May each year is announced the Clean Your Hands Day by the WHO to raise the awareness and prevent sepsis around the world, specifically in the health care sector. Take part of the information and campaign or watch...

Read More

Aptahem newsletter extra April 2018

2018-04-23

CEO comments It’s scarcely a month since our previous newsletter, but so much is happening at the moment that I wanted to give you an update on our activities earlier than planned. In this extra edition of the newsletter,...

Read More